CUV 0.72% $25.06 clinuvel pharmaceuticals limited

how times have changed

  1. 4,086 Posts.
    G'day,

    It wasnt all that long ago that an announcement like that below would put a rocket under the share price.


    EPITAN LIMITED 2003-05-20 ASX-SIGNAL-G

    HOMEX - Melbourne

    +++++++++++++++++++++++++
    EPITAN SIGNS COLLABORATION AGREEMENT TO DEVELOP TOPICAL FORMULATION
    FOR MELANOTAN(R)

    For more information contact:

    Dr Wayne Millen, CEO, EpiTan Limited, Tel: 03 9662 4688
    Mr Iain Kirkwood, Chief Administrative Officer, EpiTan Limited, Tel:
    03 9662 4688
    Mr Robert Ashley, Senior Vice President, CollaGenex, Tel: +1 215 579
    7388
    Mr Richard Allen, Monsoon Communications, Tel: 03 9620 3333
    [email protected]
    www.epitan.com.au

    MELBOURNE, AUSTRALIA

    EpiTan Limited (ASX: EPT) today announced the signing of a strategic
    collaborative agreement with CollaGenex Pharmaceuticals Inc. of
    Newtown, Pennsylvania, USA and Mr Thomas Skold of Norrtalje, Sweden
    to develop a topical formulation for its lead drug candidate,
    Melanotan(R).

    CollaGenex acquired the rights to the novel drug delivery system,
    known as Restoraderm(TM) technology, from Mr Thomas Skold, the
    inventor of the technology, in 2002. EpiTan has sub-licensed this
    technology from CollaGenex.

    This technology improves the feasibility of developing a topical
    formulation for Melanotan, as previous technology was unable to
    achieve this objective. It is envisaged a new formulation may enable
    Melanotan to be released directly into the skin and hence be
    delivered directly to the melanin producing cells.

    Mr Michael Kleinig, EpiTan's Pharmaceutical & Business Development
    Manager, said, "Working with the inventor should enable us to fast
    track this development as all of the background knowledge and know
    how will be directly available to us."

    Dr Wayne Millen, EpiTan's Managing Director, said, "This will build
    on the successful development of a single dose slow-release implant
    announced earlier this year. However, it is important that we
    continue to investigate the development of additional delivery
    mechanisms including lotions and patches. We expect Melanotan to be
    first launched onto the market with the implant. In due course, the
    successful development of a topical lotion will offer patients and
    doctors the choice of an alternative user-friendly and convenient
    delivery for Melanotan".

    "This collaboration with CollaGenex and Thomas Skold to develop a
    lotion follows the excellent progress of our current Phase IIb
    clinical trials reported recently."

    Melanotan is undergoing Phase IIb human trials in both Sydney and
    Adelaide

    --------------------------------------------------------------------------------
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$25.06
Change
0.180(0.72%)
Mkt cap ! $1.238B
Open High Low Value Volume
$24.88 $25.61 $24.84 $2.704M 107.2K

Buyers (Bids)

No. Vol. Price($)
1 400 $25.05
 

Sellers (Offers)

Price($) Vol. No.
$25.07 284 1
View Market Depth
Last trade - 16.10pm 21/02/2020 (20 minute delay) ?
(live)
Last
$25.09
  Change
0.180 ( 0.61 %)
Open High Low Volume
$24.98 $25.58 $24.97 3726
Last updated 15.59pm 21/02/2020 (live) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.